COX-2-IN-30, a benzenesulfonamide derivative, is an orally active, dual inhibitor of cyclooxygenase-2 (COX-2; IC50 = 49 nM) and cyclooxygenase-1 (COX-1; IC50 = 10.4 μM), as well as 5-lipoxygenase (5-LOX; IC50 = 2.4 μM). Additionally, it inhibits the transmembrane isoforms of human carbonic anhydrase IX and XII with nanomolar class Ki values. Demonstrating analgesic and anti-inflammatory properties, COX-2-IN-30 is devoid of acute gastric effects, avoiding ulcerogenic activity [1].

CA II (human):81.4 nM (Ki), COX-2:49 nM, CA (human):183.4 nM (Ki), 5-LOX:2.4 μM, COX-1:10.4 μM, CA XII (human):21.6 nM (Ki), CA IX (human):38.4 nM (Ki)

COX-2-IN-30（化合物7a）具有选择性地与hCA亚型结合的能力，其K i 值分别为hCA I的183.4 nM、hCA II的81.4 nM、hCA IX的38.4 nM以及hCA XII的21.6 nM [1]。

COX-2-IN-30（化合物7a）（10 mg/kg；口服；单剂量）在药理学研究中显示出镇痛效果，能明显减少小鼠扭体次数[1]。在Carrageenan诱发的大鼠爪水肿实验中，此化合物显著降低爪部肿胀[1]。此外，COX-2-IN-30有效降低了TNF-α和IL-1β的水平[1]，并且在单剂量口服后，在雄性白化病大鼠的胃组织中显示出良好的安全性[1]。